Report: Target Product Profiles: Physician Insights on Key Attributes - Ovarian Cancer (Advanced), An agent or regimen that offers increased median overall survival compared with paclitaxel/carboplatin for the treatment of advanced ovarian cancer TOC

Target Product Profiles: Physician Insights on Key Attributes - Ovarian Cancer (Advanced), An agent or regimen that offers increased median overall survival compared with paclitaxel/carboplatin for the treatment of advanced ovarian cancer

Published by

Decision Resources, Inc.

Published

2008/03

Content info

36 Pages

Product code

DR65866

Price

From US $ 5625

PDF by E-Mail

Approx. 1-2 business days

Hard Copy/CD-ROM

Approx. 3-4 business days

If you need expedited delivery, please call us.

Introduction
- Using Target Product Profiles in Your Market Strategy
- Report Contents
- Target Product Profile Methodology
Etiology and Pathophysiology
- Overview
- Etiology
  - Genetic Risk Factors
- Pathophysiology
  - Characterization of Ovarian Epithelial Tumors
  - Spread of Ovarian Cancer
  - Signs and Symptoms
  - Staging
  - Prognostic Factors
Target Product Profile Discussion-Advanced Ovarian Cancer
- Target Product Profile Summary for Advanced Ovarian Cancer-2011
- Assessing Drug Development Opportunities
- Physician Survey Results
  - Effi cacy
  - Safety and Tolerability
  - Delivery
  - Estimated Patient Share
- Pricing Potential
- Forecasted 2016 Pricing Environment
- Competitors to Watch
- Emerging Product Profiles

Target Product Profiles: Physician Insights on Key Attributes - Ovarian Cancer (Advanced), An agent or regimen that offers increased median overall survival compared with paclitaxel/carboplatin for the treatment of advanced ovarian cancer

Table of Contents